Boothbay Fund Management’s Adicet Bio ACET Stock Holding History

Boothbay Fund Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,419	Closed	-$397K	–	2242
2021 Q4	$397K	Buy	+1,419	New	+$244K	0.01%	1116

Other funds holding ACET

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boothbay Fund Management's ACET Position: Q3 2022 in Review

Boothbay Fund Management sold out of Adicet Bio (ACET) in Q3 2022, closing a stake of 895 shares — an estimated $209K sold.

Boothbay Fund Management first reported a position in ACET in Q2 2019 and held it in 10 quarters. The position peaked at $1.01M in Q1 2022. 102 funds tracked by Wall St. Rank hold ACET as of Q3 2022.

Boothbay Fund Management reported no remaining Adicet Bio position as of Q3 2022 after selling out during the quarter.
Boothbay Fund Management sold 895 Adicet Bio shares in Q3 2022, an estimated $209K.
Boothbay Fund Management first reported a position in Adicet Bio in Q2 2019 and held it in 10 quarters.
Boothbay Fund Management's Adicet Bio position peaked at $1.01M in Q1 2022.
102 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.